UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook
In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.
In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”
Bristol-Myers Squibb Co. closed on Tuesday at $40.83.
Latest Ratings for BMY
|Oct 2016||Hilliard Lyons||Upgrades||Neutral||Long-Term Buy|
|Oct 2016||Credit Suisse||Maintains||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.